Moderna (MRNA) Competitors

93.3% of Robinhood Markets shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 13.5% of Robinhood Markets shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Robinhood Markets has a beta of 2.35, meaning that its stock price is 135% more volatile than the broader market. Comparatively, Moderna has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

Robinhood Markets presently has a consensus target price of $120.52, suggesting a potential upside of 29.19%. Moderna has a consensus target price of $42.13, suggesting a potential downside of 28.79%. Given Robinhood Markets' stronger consensus rating and higher possible upside, equities analysts clearly believe Robinhood Markets is more favorable than Moderna.

Robinhood Markets has a net margin of 42.01% compared to Moderna's net margin of -141.43%. Robinhood Markets' return on equity of 22.43% beat Moderna's return on equity.

In the previous week, Moderna had 15 more articles in the media than Robinhood Markets. MarketBeat recorded 57 mentions for Moderna and 42 mentions for Robinhood Markets. Robinhood Markets' average media sentiment score of 0.66 beat Moderna's score of 0.49 indicating that Robinhood Markets is being referred to more favorably in the media.

Robinhood Markets has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Robinhood Markets, indicating that it is currently the more affordable of the two stocks.

In the previous week, Moderna had 32 more articles in the media than Novavax. MarketBeat recorded 57 mentions for Moderna and 25 mentions for Novavax. Moderna's average media sentiment score of 0.49 beat Novavax's score of 0.22 indicating that Moderna is being referred to more favorably in the media.

Moderna currently has a consensus price target of $42.13, suggesting a potential downside of 28.79%. Novavax has a consensus price target of $13.00, suggesting a potential upside of 63.52%. Given Novavax's stronger consensus rating and higher probable upside, analysts plainly believe Novavax is more favorable than Moderna.

Novavax has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Moderna has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Novavax has a beta of 2.47, suggesting that its stock price is 147% more volatile than the broader market.

75.3% of Moderna shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 10.8% of Moderna shares are held by insiders. Comparatively, 1.6% of Novavax shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Novavax has a net margin of -59.87% compared to Moderna's net margin of -141.43%. Novavax's return on equity of -14.82% beat Moderna's return on equity.

Moderna has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, Ocugen has a beta of 2.21, suggesting that its share price is 121% more volatile than the broader market.

In the previous week, Moderna had 46 more articles in the media than Ocugen. MarketBeat recorded 57 mentions for Moderna and 11 mentions for Ocugen. Moderna's average media sentiment score of 0.49 beat Ocugen's score of -0.12 indicating that Moderna is being referred to more favorably in the media.

Ocugen has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Ocugen's return on equity.

Moderna presently has a consensus target price of $42.13, indicating a potential downside of 28.79%. Ocugen has a consensus target price of $9.50, indicating a potential upside of 648.03%. Given Ocugen's stronger consensus rating and higher probable upside, analysts plainly believe Ocugen is more favorable than Moderna.

75.3% of Moderna shares are held by institutional investors. Comparatively, 10.3% of Ocugen shares are held by institutional investors. 10.8% of Moderna shares are held by insiders. Comparatively, 4.0% of Ocugen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Ocugen has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Regeneron Pharmaceuticals has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market. Comparatively, Moderna has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Regeneron Pharmaceuticals currently has a consensus target price of $797.75, suggesting a potential upside of 1.71%. Moderna has a consensus target price of $42.13, suggesting a potential downside of 28.79%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Moderna.

In the previous week, Moderna had 10 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 57 mentions for Moderna and 47 mentions for Regeneron Pharmaceuticals. Moderna's average media sentiment score of 0.49 beat Regeneron Pharmaceuticals' score of 0.41 indicating that Moderna is being referred to more favorably in the news media.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Moderna's net margin of -141.43%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Moderna's return on equity.

Regeneron Pharmaceuticals has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.